JP Patent

JP2020530851A — Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ−２抗体との組み合わせ

Assigned to MedImmune Ltd · Expires 2020-10-29 · 6y expired

What this patent protects

本発明は、Ｔ７９０Ｍ陽性ＥＧＦＲ変異非小細胞肺癌の治療のための抗ヒトＶＥＧＦＲ−２抗体とヒトＥＧＦＲチロシンキナーゼ阻害剤との組み合わせに関する。

USPTO Abstract

本発明は、Ｔ７９０Ｍ陽性ＥＧＦＲ変異非小細胞肺癌の治療のための抗ヒトＶＥＧＦＲ−２抗体とヒトＥＧＦＲチロシンキナーゼ阻害剤との組み合わせに関する。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: JP2020530851A
Jurisdiction: JP
Classification: —
Expires: 2020-10-29
Drug substance claim: No
Drug product claim: No
Assignee: MedImmune Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.